EIF2AK3 and hepatocellular carcinoma: Overall, these findings suggest that while sorafenib and lenvatinib effectively inhibit key signaling pathways in uninfected hepatoma cells, HBV infection alters their impact, potentially contributing to drug resistance through distinct mechanisms involving PERK and pAKT signaling pathways.